Clinical characteristics
From January 2009 to June 2019, a total of 35 children with POST-TEXT
III and IV hepatoblastoma were treated, including 24 males and 11
females, with an average age of 23.89 ± 22.87 months (2-91 months).
Serum AFP was significantly higher than normal in all cases, of which
only 1 (2.9%) case was <1000ug/L, 8 (22.8%) cases
were1000-100,000 ug/L, and 26 (74.3%) cases were >
100000ug/L. There were 1, 31, and 3 cases of PRETEXT II, III, and IV,
including 5 cases of lung metastasis. Tumor biopsy was performed in 27
patients (77.1%). The tumor volume before treatment was 105.23-1235.06
cm3, with an average volume of 568.99 ± 285.56
cm3.
There were 34 and 1 cases of POST-TEXT III and IV, respectively. One
case of PRETEXT II was upgraded to POST-TEXT IV, and 3 cases of PRETEXT
IV were downgraded to POST-TEXT III (Table 1). Neoadjuvant chemotherapy
was performed in 8 patients (22.9%) within 2 cycles; 22 patients
(62.9%) within 4 cycles; 5 patients (14.3%) within 6 cycles. The
relationship between tumor preoperative cycles and stage is shown in
Table 1. The tumor volume after chemotherapy was 20.66-1235.77
cm3, with an average volume of 272.64 ± 2569.19
cm3, of which the volume was reduced by 30 cases
(85.7%), and the average size was reduced by 67.45% ± 14.98%; the
volume was increased by 5 cases (14.3%), and the average size was
increased by 92.14 % ± 74.71%. The relationship between tumor volume
change and stage is shown in Table 1.